Roche publishes its latest results from Pivotal SUNFISH Part 2 with Risdiplam. Another milestone is the treatment of adult patients with spinal muscular atrophy type 2 and 3.
Roche’s risdiplam showed significant improvement in motor function in people
aged 2-25 with type 2 or 3 spinal muscular atrophy
• First placebo-controlled trial to include adults with SMA demonstrates risdiplam improved or
stabilised motor function
• Medically meaningful and statistically significant results in primary and key secondary
endpoints
• Pivotal SUNFISH Part 2 study population represents broad, real-world spectrum of people living with SMA